Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 8.64M P/E - EPS this Y - Ern Qtrly Grth -
Income -18.15M Forward P/E - EPS next Y - 50D Avg Chg -40.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -68.00%
Dividend N/A Price/Book 3.25 EPS next 5Y - 52W High Chg -94.00%
Recommedations - Quick Ratio 1.35 Shares Outstanding 7.78M 52W Low Chg 2.00%
Insider Own 12.60% ROA -258.30% Shares Float 6.80M Beta -
Inst Own 1.75% ROE -975.03% Shares Shorted/Prior 637.72K/552.33K Price 0.59
Gross Margin - Profit Margin - Avg. Volume 751,298 Target Price -
Oper. Margin - Earnings Date - Volume 191,063 Change -7.28%
About PaxMedica, Inc.

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

PaxMedica, Inc. News
05/15/24 PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
05/07/24 PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
04/26/24 PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
04/23/24 PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
04/16/24 PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
04/11/24 PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
03/13/24 PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
01/18/24 IBN Highlights PaxMedica's Video Release on Transformative ASD Study
01/17/24 PaxMedica on Promising Path to Address Unmet ASD Needs
12/22/23 PaxMedica Files 8-K Following Nasdaq Compliance Achievement
09:30 AM PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline
12/12/23 PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report
12/08/23 PaxMedica CEO Featured in Just-Released Fireside Chat Video
12/07/23 PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline
12/06/23 PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
12/01/23 PaxMedica Closes on Public Offering Reaching Estimated $7M
11/22/23 PaxMedica Announces Closing of $7.0 Million Public Offering
11/22/23 PaxMedica Announces Pricing of $7M Public Offering
11/21/23 PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast
11/20/23 PaxMedica Announces Pricing of $7.0 Million Public Offering
PXMD Chatroom

User Image NetworkNewsWire Posted - 6 days ago

BioMedNewsBreaks — $PXMD Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply https://ibn.fm/ma69x #PaxMedica #Healthcare

User Image NetworkNewsWire Posted - 1 week ago

Researchers Say Brain 'Overgrowth' Could Contribute to Autism Development $PXMD https://ibn.fm/hQgIe #biomedstocks #Autism

User Image EsquireTradingCo Posted - 2 weeks ago

$ANVS Looks like our investor relations guy is associated with some OTC pigs $VENG and $PXMD

User Image Neverahappy Posted - 2 weeks ago

$PXMD if win deliating appeal this fly

User Image NetworkNewsWire Posted - 05/29/24

$PXMD Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA https://ibn.fm/Zc0pL

User Image Neverahappy Posted - 05/29/24

$PXMD

User Image JuliVeytsman Posted - 05/24/24

$PXMD

User Image Neverahappy Posted - 05/24/24

$PXMD

User Image NetworkNewsWire Posted - 05/24/24

$PXMD Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis https://ibn.fm/JtRcm

User Image NetworkNewsWire Posted - 05/24/24

Study Discovers Elevated Risk of Toxicity Among Autistic Kids $PXMD https://ibn.fm/Z4rpP #biomedstocks #children

User Image Neverahappy Posted - 05/23/24

$PXMD

User Image Robere Posted - 05/23/24

$PXMD Good info

User Image NetworkNewsWire Posted - 05/22/24

BioMedNewsBreaks — $PXMD Dedicated to Ensuring Access to Life-Saving Treatments https://ibn.fm/tOxKy #PaxMedica #HealthcareSolutions

User Image Anakin95 Posted - 05/21/24

$PXMD definitely a good start let's try and double that trmw and into the week

User Image Neverahappy Posted - 05/21/24

$PXMD

User Image rakic99 Posted - 1 month ago

$PXMD

User Image Anakin95 Posted - 1 month ago

$PXMD good news

User Image NetworkNewsWire Posted - 1 month ago

$PXMD - PaxMedica Inc. Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting https://ibn.fm/nRpfn #HealthTech #HealthcareSolutions

User Image Neverahappy Posted - 1 month ago

$PXMD

User Image JMacky Posted - 1 month ago

$PXMD https://www.paxmedica.com/press-releases/paxmedica-files-nasdaq-delisting-appeal-notice-and-prepares-for-upcoming-fda-meeting-on-pax-101

User Image Unalloyed Posted - 1 month ago

$PXMD http://archive.fast-edgar.com/20240515/ALB2K22C8Z22KTZ222TG2ZZZM9BIR2U2D262/tm2414545d1_ex99-1.htm

User Image Stock_Titan Posted - 1 month ago

$PXMD PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 https://www.stocktitan.net/news/PXMD/pax-medica-files-nasdaq-delisting-appeal-notice-and-prepares-for-44u1h7lhyxwz.html

User Image StockStreet Posted - 1 month ago

$PXMD 1. NASDAQ gave them till Dec 24 2024 for compliance. Why Nasdaq delisted them now? 2. Annual shareholders meeting on 23 May 2024. With vote on RS up to a ratio 1 for 25. The reasons given for the vote (avoid delisting) no longer there, since they already been delisted. Would they keep the RS vote on the agenda or abandon it. They might keep it on the meeting's agenda, if they will seek relisting. These are just couple of thoughts on this ticker, but surely there are many too many unknowns here and there. Why the ambiguity. This a public company. More corporate transperancy, is much needed. GL

User Image NetworkNewsWire Posted - 1 month ago

Researcher Wants to Untangle Environmental, Genetic Complexities of Autism $PXMD https://ibn.fm/BuKUJ #biomedstocks #autism

User Image TBoneP Posted - 1 month ago

$PXMD RIP

User Image Stock_Titan Posted - 1 month ago

$PXMD PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy https://www.stocktitan.net/news/PXMD/pax-medica-provides-company-update-and-continues-to-advance-pax-101-vslobk1fsj1f.html

User Image iambaron Posted - 1 month ago

$PXMD could be a buyout but that’s just hopeful thinking. No position

User Image JMacky Posted - 1 month ago

$PXMD will the company release a statement about any of this today?

User Image The_Colonel Posted - 1 month ago

$PXMD Why didn't this open for trading this morning?

User Image Jamuary Posted - 1 month ago

$PXMD what’s our options here?! Sell with loss or transfer to OTC stock broker?! Any advise?!

Analyst Ratings
HC Wainwright & Co. Buy Dec 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rome Zachary Director Director Jan 29 Sell 0.48 811 389 15,148 01/31/24
LaRochelle Karen Director Director Jan 29 Sell 0.48 78 37 2,829 01/31/24
Coelho John F Director Director Jan 29 Sell 0.48 27 13 4,615 01/31/24
Weisman Howard J. Chief Executive Offi.. Chief Executive Officer Jan 29 Sell 0.47 372 175 37,675 01/31/24
Rome Zachary Director Director Oct 27 Sell 0.1848 16,301 3,012 277,390 10/30/23
Derby Michael 10% Owner 10% Owner Oct 27 Sell 0.1897 9,175 1,740 439,171 10/30/23
Coelho John F Director Director Oct 27 Sell 0.1895 570 108 79,090 10/30/23
LaRochelle Karen Director Director Oct 27 Sell 0.189 1,679 317 49,994 10/30/23
Weisman Howard J. Chairman and CEO Chairman and CEO Oct 27 Sell 0.1894 8,049 1,524 649,549 10/30/23
Weisman Howard J. Chief Executive Offi.. Chief Executive Officer Mar 08 Sell 1.45 35,892 52,043 541,633 03/09/23
Rome Zachary Chief Operating Offi.. Chief Operating Officer Mar 08 Sell 1.46 33,405 48,771 288,452 03/09/23
Derby Michael Executive Chairman Executive Chairman Mar 09 Sell 1.43 2,143 3,064 324,430 03/09/23
LaRochelle Karen Director Director Mar 09 Sell 1.48 335 496 42,415 03/09/23
Coelho John F Director Director Mar 09 Sell 1.48 130 192 67,235 03/09/23
Weisman Howard J. Chief Executive Offi.. Chief Executive Officer Mar 06 Sell 1.63 37,140 60,538 577,525 03/07/23
Rome Zachary Chief Operating Offi.. Chief Operating Officer Mar 06 Sell 1.63 36,992 60,297 321,857 03/07/23
Derby Michael Executive Chairman Executive Chairman Mar 06 Sell 1.64 28,962 47,498 326,573 03/07/23
Coelho John F Director Director Mar 02 Sell 1.93 3,013 5,815 67,365 03/03/23
LaRochelle Karen Director Director Mar 02 Sell 1.92 8,833 16,959 42,750 03/03/23
Weisman Howard J. Chief Executive Offi.. Chief Executive Officer Mar 02 Sell 1.92 27,002 51,844 614,665 03/03/23
Rome Zachary Chief Operating Offi.. Chief Operating Officer Mar 02 Sell 1.92 26,151 50,210 358,849 03/03/23
Derby Michael Executive Chairman Executive Chairman Mar 02 Sell 1.92 29,465 56,573 355,535 03/03/23